2-Isopropyl-2.3-dihydro-pyran | 16765-50-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环化合物
• 英文名称: 2-Isopropyl-2.3-dihydro-pyran
• 英文别名: 2-propan-2-yl-3,4-dihydro-2H-pyran
• CAS: 16765-50-7
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: HIOUNBVULZFXMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Isopropyl-2.3-dihydro-pyran 在 水 作用下， 生成 5-hydroxy-6-methyl-heptanal
  参考文献：
  名称：

  Colonge,J.; Girantet,A., Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1962, vol. 254, p. 498 - 500

  摘要：

  DOI：

文献信息

• [EN] N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS<br/>[FR] DÉRIVÉS N-PYRIDINYL ACÉTAMIDE COMME INHIBITEURS DE LA OIE DE SIGNALISATION WNT
  申请人：REDX PHARMA PLC

  公开号：WO2016055790A1

  公开（公告）日：2016-04-14

  This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.

  这项发明涉及化合物。更具体地，该发明涉及作为Wnt信号通路抑制剂的化合物。具体来说，该发明考虑了Porcupine（Porcn）的抑制剂。此外，该发明考虑了制备这些化合物的过程以及这些化合物的用途。因此，该发明的化合物可用于治疗由Wnt信号通路介导的疾病，例如治疗癌症、肉瘤、黑色素瘤、皮肤癌、血液肿瘤、淋巴瘤、癌症和白血病；或增强抗癌治疗的有效性。
• [EN] N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY<br/>[FR] DÉRIVÉS DE N-PYRIDYL ACÉTAMIDE UTILISÉS COMME INHIBITEURS DE LA VOIE DE SIGNALISATION WNT
  申请人：REDX PHARMA PLC

  公开号：WO2016055786A1

  公开（公告）日：2016-04-14

  This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.

  这项发明涉及化合物。更具体地，该发明涉及作为Wnt信号通路抑制剂的化合物。具体来说，该发明考虑了Porcupine（Porcn）的抑制剂。此外，该发明考虑了制备这些化合物的过程以及这些化合物的用途。因此，该发明的化合物可用于治疗由Wnt信号通路介导的疾病，例如治疗癌症、肉瘤、黑色素瘤、皮肤癌、血液肿瘤、淋巴瘤、癌症和白血病；或增强抗癌治疗的有效性。
• Purine compounds and methods of use thereof
  申请人：Salzman L. Andrew

  公开号：US20070238694A1

  公开（公告）日：2007-10-11

  The invention relates to Purine Compounds; compositions comprising an effective amount of a Purine Compound; and methods for reducing a subject's rate of metabolism or protecting a subject's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, diabetes, a cellular proliferative disorder, a skin disorder, a radiation-induced injury, a wound or an inflammatory disease comprising administering an effective amount of a Purine Compound to a subject in need thereof.

  这项发明涉及嘌呤化合物；包含有效量嘌呤化合物的组合物；以及用于减少受试者代谢率或在心脏停搏期间保护受试者心脏免受心肌损伤，或用于治疗或预防心血管疾病、神经系统紊乱、缺血情况、再灌注损伤、肥胖、消耗性疾病、糖尿病、细胞增殖紊乱、皮肤疾病、辐射诱导损伤、创伤或炎症疾病的方法，包括向需要的受试者施用有效量的嘌呤化合物。
• N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors
  申请人：Redx Pharma PLC

  公开号：US10202375B2

  公开（公告）日：2019-02-12

  Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.

  本发明公开了可用作 Wnt 信号通路抑制剂的化合物。具体来说，本发明考虑使用 Porcupine（Porcn）抑制剂。此外，本发明还考虑了制备化合物的工艺和化合物的用途。因此，本发明的化合物可用于治疗由 Wnt 信号通路介导的病症，例如治疗癌症、肉瘤、黑色素瘤、皮肤癌、血液肿瘤、淋巴瘤、癌和白血病；或增强抗癌治疗的效果。
• N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway
  申请人：Redx Pharma PLC

  公开号：US10793560B2

  公开（公告）日：2020-10-06

  Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.

  本发明公开了可用作 Wnt 信号通路抑制剂的化合物。具体而言，本发明考虑使用 Porcupine（Porcn）抑制剂。此外，本发明还考虑了制备化合物的工艺和化合物的用途。因此，本发明的化合物可用于治疗由 Wnt 信号通路介导的病症，例如治疗癌症、肉瘤、黑色素瘤、皮肤癌、血液肿瘤、淋巴瘤、癌和白血病；或增强抗癌治疗的效果。